LeMaitre Vascular, Inc. (LMAT) to Issue Quarterly Dividend of $0.20 on March 27th

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Tuesday, February 18th, Wall Street Journal reports. Investors of record on Thursday, March 13th will be given a dividend of 0.20 per share by the medical instruments supplier on Thursday, March 27th. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, March 13th. This is a 25.0% increase from LeMaitre Vascular’s previous quarterly dividend of $0.16.

LeMaitre Vascular has increased its dividend payment by an average of 13.3% annually over the last three years and has increased its dividend annually for the last 14 consecutive years. LeMaitre Vascular has a payout ratio of 32.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect LeMaitre Vascular to earn $2.17 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 36.9%.

LeMaitre Vascular Stock Up 0.6 %

Shares of LMAT opened at $81.88 on Tuesday. LeMaitre Vascular has a 52 week low of $62.39 and a 52 week high of $109.58. The stock has a market cap of $1.85 billion, a P/E ratio of 44.74, a P/E/G ratio of 2.22 and a beta of 0.89. The business’s 50 day moving average price is $96.07 and its 200-day moving average price is $94.92.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. On average, equities analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Wells Fargo & Company began coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Lake Street Capital upped their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and a consensus price target of $95.25.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.